Literature DB >> 15993650

The influence of adenovirus fiber structure and function on vector development for gene therapy.

Stuart A Nicklin1, Eugene Wu, Glen R Nemerow, Andrew H Baker.   

Abstract

The collective attributes of adenoviruses (Ads), including ease of accomplishing replication deficiency, readily achievable high titers, encoding of large expression cassettes, efficiency of gene delivery to most cell types, and well-characterized biology, have made Ads, particularly Ad serotype 5 (Ad 5), some of the most utilized vectors for gene delivery. In recent years, however, it has become apparent that additional aspects of basic Ad virology must be uncovered for this vector system to succeed in the clinic. While local gene delivery is generally efficient, the broad tropism of Ad 5 and its tendency to home to the liver after systemic administration have proved to be limitations for other therapeutic applications, such as the treatment of disseminated cancers and cardiovascular disease. This has refocused research into the biology of Ad capsid components, particularly the main tropism determinant, the fiber/penton base complex, and their influence on transduction of selected cell types in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993650     DOI: 10.1016/j.ymthe.2005.05.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  59 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

4.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 5.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

6.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Serratia proteamaculans Strain AGR96X Encodes an Antifeeding Prophage (Tailocin) with Activity against Grass Grub (Costelytra giveni) and Manuka Beetle (Pyronota Species) Larvae.

Authors:  Mark R H Hurst; Amy Beattie; Sandra A Jones; Aurelie Laugraud; Chikako van Koten; Lincoln Harper
Journal:  Appl Environ Microbiol       Date:  2018-05-01       Impact factor: 4.792

8.  Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Authors:  Jenny A Greig; Suzanne Mk Buckley; Simon N Waddington; Alan L Parker; David Bhella; Rebecca Pink; Ahad A Rahim; Takashi Morita; Stuart A Nicklin; John H McVey; Andrew H Baker
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 9.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

10.  Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Authors:  Anne K Zaiss; Erin M Foley; Roger Lawrence; Lina S Schneider; Hamidreza Hoveida; Patrick Secrest; Arthur B Catapang; Yu Yamaguchi; Ramon Alemany; Dmitry M Shayakhmetov; Jeffrey D Esko; Harvey R Herschman
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.